Probi signed major agreement for launch of Functional Food product in North America

Probi has signed a major agreement with a Global FMCG-company (fast-moving consumer goods) for their launch of a Functional Food product containing Probi’s bacteria for gut health in North America and potentially other territories.

Launch of the product, under a leading brand within its category, is planned for the second half of 2019 in the North American market. The agreement is expected to have significant impact on future revenues and earnings in Probi’s Functional Food business area. In 2016, Probi had net sales of 35 MSEK in the Functional Food business area, corresponding to 8% of total net sales.

This information is information that Probi AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out below, at 12 December 2017 at 08.00 CET.

FOR FURTHER INFORMATION, CONTACT:
Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23, e-mail: peter.nahlstedt@probi.com
Jörn Andreas, CFO, Probi, tel +46 46 286 89 41, e-mail: jorn.andreas@probi.com
Niklas Brandt, CIO & Investor relations, Probi, tel +46 46 286 89 26, e-mail: niklas.brandt@probi.com

ABOUT PROBI
Probi AB is a Swedish publicly traded bioengineering company. The vision of Probi is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company with four centers of excellence, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2016, Probi had net sales of MSEK 444. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi has about 5,000 shareholders. Read more at www.probi.se. 

Tags:

About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.

Contacts

Subscribe

Documents & Links